Galapagos seeks ‘strategic options’ for Jyseleca as JAK inhibitor sales disappoint again

Galapagos is assessing “various strategic options” with Jyseleca, the JAK inhibitor that once inspired blockbuster projections but repeatedly disappointed.

The Belgian biotech attributed the move to the EU’s recent recommendations to limit the use of JAK inhibitors, noting major side effects such as malignancy, major adverse cardiovascular events, serious…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks